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Autoinflammatory and autoimmune disorders are charac- 
terized by chronic activation of the immune system, which 
leads to systemic self-directed inflammation in genetically 
predisposed individuals. Mutations in inflammasome-related 
proteins have been associated with autoinflammatory disorders, 
and the link between inflammasome and autoimmune disorders 
is becoming increasingly clear. As researchers learn more about 
these two areas, other disorders that were once thought to be 
autoimmune are now being considered autoinflammatory, 
or as having at least an autoinflammatory component. This 
review depicts the role of interleukin-1 as “Ariadne’s thread” 
on the path through the labyrinth of autoinflammatory and 
autoimmune disorders and emphasizes the blurred boundary 
between innate and adaptive immune systems.
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i nterleukin-1 (IL-1), the first cytokine discovered (in the 1980s), is a potent mediator of inflammation. It coordinates 
systemic host defense responses to pathogens or various inju-
ries, and the whole IL-1 system represents an attractive target 
for different therapeutic interven-
tions. The identification of a new 
cytoplasmic complex of proteins, 
called inflammasomes which sense 
intracellular danger- or pathogen-
associated molecular patterns 
and regulate IL-1β activation and secretion, has enhanced our 
understanding of the role of IL-1 in biology and many disease 
processes. Dysregulation of the inflammasome is the cause of 
a family of monogenic autoinflammatory disorders. This dys-
regulation has also been involved in the pathogenesis of differ-
ent multifactorial polygenic diseases with an autoinflammatory 
component, and even in different autoimmune diseases. 
Classical autoimmune disorders are associated with the 
presence of autoantibodies and autoantigen-specific T cells; 
however, in addition to the classical major histocompatibility 
complex (MHC) class II-associated diseases, such as systemic 
lupus erythematosus and rheumatoid arthritis, the autoim-
munity paradigm has also been the dominant conceptual 
framework when considering the pathogenesis of a range of 
other chronic inflammatory conditions, such as inflammatory 
bowel disease and systemic onset juvenile idiopathic arthritis. 
Several difficulties arise when the autoimmunity concept 
is evoked to describe the self-directed tissue inflammation 
encountered in many diseases, such as hereditary periodic 
fevers, now framed in the context of autoinflammatory disor-
ders, for which autoantibody, autoreactive T cells, and MHC 
allelic associations are lacking [1].
from monogenic to multifactorial  
autoinflammatorY disorders
Advances in cellular and molecular biology have revealed that 
impaired control of innate immune system generates the so-
called autoinflammatory disorders, a group of heritable diseases 
characterized by unprovoked attacks of systemic inflammation in 
the absence of autoantibodies and 
autoreactive T cells [2]. Following 
the discovery of the familial Med- 
iterranean fever (FMF) gene in 
1997 and the tumor necrosis factor 
(TNF) receptor-associated peri-
odic syndrome (TRAPS) gene in 1999, there has been an extraor-
dinary revolution in the understanding of monogenic autoin-
flammatory disorders, with identification of multiple genes and 
new clinical entities, all characterized by subverted mechanisms 
of inflammation. Their unifying pathogenetic mechanism is a 
dysregulation of the inflammasome, which leads to overproduc-
tion of IL-1β [3]. At a clinical level, autoinflammatory disorders 
dysregulation of the inflammasome is 
the pivotal cause in the pathogenesis of 
autoinflammatory disorders and seems  
also to participate in different  
systemic autoimmune conditions
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are defined by recurrent fever attacks with constantly increased 
acute-phase reactants and several inflammatory phenomena 
involving skin, joints, serosal membranes, etc., that usually start 
in childhood and are mostly induced by IL-1β-directed pro-
inflammatory cascade. Therefore, monotherapy with blocking 
IL-1 agents often leads to a reduction in disease severity in most 
autoinflammatory disorders [4]. Table 1 presents a list of the 
most recent clinical trials on this group of diseases. 
Recent advances in our knowledge on the pathogenesis of 
many multifactorial polygenic disorders with a presumed auto-
inflammatory component have paved the way for the introduc-
tion of novel therapeutic modalities. 
Type 2 diabetes mellitus (T2DM) is 
profoundly influenced by inflam-
masome activation-dependent IL-1 
release: high serum concentrations of glucose lead to increased 
IL-1β production in human β cells, which is followed by NF-kB 
activation, Fas signaling up-regulation, and β cell apoptosis. 
Different scientists have found that oligomers of islet amyloid 
polypeptide, a protein deposited in the pancreas of patients with 
T2DM, might trigger NLRP3 inflammasome, enhancing mature 
IL-1β production and resulting in a progressive decrease in the 
number of β cells [5]. Several studies have also been performed 
to prove IL-1 blockade as an effective strategy for β cell func-
tion and glycemic control [6]. Other evidence derives from 
the positive effects of a single dose of canakinumab on HbA1c 
levels [7]. Clinical trials are in progress to determine whether 
gevokizumab might improve glycemic control in subjects with 
T2DM in combination with metformin (ClinicalTrials.gov 
NCT01144975, NCT01066715, NCT00513214) [8]. However, 
further results are needed to give anti-IL1 agents a role in the 
management of T2DM. 
Patients with idiopathic recurrent acute pericarditis (IRAP) 
are usually characterized by absence of autoantibodies or self-
reactive T cells, and are brilliant responders to IL-1 inhibition 
[9]. In addition, IRAP may occur in patients with FMF and 
TRAPS, disclosing the diagnosis of these two autoinflamma-
tory disorders [10], and may also be the only clinical symptom 
in patients carrying low-penetrance TRAPS-related mutations 
[11]. A multicenter study evaluating the incidence of TRAPS 
mutations in patients with IRAP has 
demonstrated that positive family 
history of pericarditis, failure of 
treatment with colchicine, and need 
for immunosuppressive agents are crucial diagnostic clues [12]. 
Fifteen young patients with IRAP were evaluated after treat-
ment with anakinra, revealing a 95% reduction in recurrences 
[13]. A phase IV study to prove anakinra efficacy in patients 
with IRAP is ongoing (ClinicalTrials.gov NCT02219828). 
Many pro-inflammatory cytokines have a critical role 
in orchestrating the body’s reaction to monosodium urate 
(MSU) and calcium pyrophosphate dihydrate crystals: both 
these crystals activate the NLRP3 inflammasome, resulting in 
intense production of bioactive IL-1β [14]. Further evidence 
for the role of IL-1β in the pathogenesis of gout is shown by 
the demonstration that IL-1β receptor-deficient mice are not 
susceptible to MSU-induced inflammation. Further proof of 
the concept that IL-1 is basically involved in patients with gout 
table 1. Cinical trials in progress related to interleukin-1 blockade in the monogenic autoinflammatory disorders
Phase status study disease
clinical trial.gov 
identifier
Anakinra 3 Recruiting Anakinra in adult patients with colchicine-resistant FMF FMF NCT01705756
1 Completed The use of anakinra in the treatment of familial cold autoinflammatory syndrome FCAS NCT00214851
Canakinumab 3 Recruiting Efficacy, safety and tolerability of ACZ885 in pediatric patients with the following cryopyrin-associated periodic 
syndromes: familial cold autoinflammatory syndrome, Muckle-Wells syndrome and CINCA syndrome
CAPS NCT01576367
3 Completed The safety and efficacy of canakinumab in patients aged ≥ 4 years diagnosed with cryopyrin-associated periodic 
syndromes in Canada
CAPS NCT01105507
3 Completed Efficacy and safety study of canakinumab administered for 6 months (24 weeks) in Japanese patients with cryopyrin-
associated periodic syndromes followed by an extension phase
CAPS NCT00991146
2 Completed Evaluation of  the safety and efficacy of canakinumab in pediatric patients with colchicine-intolerant or colchicine-
resistant FMF
FMF NCT01148797
2 Completed Efficacy and safety of canakinumab in patients with colchicine-resistant FMF FMF NCT01088880
3 Active Efficacy, safety and tolerability of ACZ885 in pediatric patients with the following cryopyrin-associated periodic 
syndromes: familial cold autoinflammatory syndrome, Muckle-Wells syndrome and CINCA syndrome
CAPS NCT01302860
– Recruiting Clinical outcomes and safety: a registry study of canakinumab patients (B-confident) CAPS NCT01213641
2 Active Canakinumab in patients with active hyper-IgD syndrome MKD NCT01303380
2 Completed Efficacy and safety study of ACZ885 in patients with tumor necrosis factor receptor-associated periodic syndrome TRAPS NCT01242813
3 Recruiting Efficacy and safety of canakinumab in patients with hereditary periodic fevers HPFs NCT02059291
CAPS = cryopyrin-associated periodic syndromes, FMF = familial Mediterranean fever, HPFs = hereditary periodic fever syndromes, MKD = mevalonate kinase deficiency 
syndrome, TRAPS = tumor necrosis factor receptor-associated periodic syndrome
interleukin-1 plays a critical role in the 
complex pathways linking innate  
and adaptive immune systems
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by Th-17 cells and directed by many pro-inflammatory 
cytokines, chiefly TNFα and IL-1β [26]. In fact, anakinra, 
canakinumab and gevokizumab might suppress immune 
mediated ocular inflammation not only in animal models 
but also in different diseases in which severe uveitis is part 
of the clinical spectrum, such as Blau syndrome, early-onset 
sarcoidosis, and BD [27-29]. Three multicenter phase III 
clinical trials are underway to test the safety and efficacy 
of gevokizumab in treating active non-infectious uveitis 
(ClinicalTrials.gov NCT01684345), quiescent non-infectious 
uveitis (ClinicalTrials.gov NCT01747538), and BD-associated 
uveitis (ClinicalTrials.gov NCT01965145), whereas a phase II 
clinical trial with gevokizumab is presently being conducted 
for patients with scleritis (ClinicalTrials.gov NCT01835132). 
The pathogenesis of BD is still unknown, and continuous 
efforts are in progress to characterize its biologic background 
where genetic and environmental factors cooperate, suggesting 
that the disease lies probably at the crossroad between autoim-
mune and autoinflammatory syndromes. The role of innate 
immunity in BD has been suggested not only by increased levels 
of IL-1 in both serum and syno-
vial fluid but also by the relevant 
effect obtained with IL-1 inhibi-
tion [30]. A pilot study is cur-
rently testing the clinical efficacy 
of anakinra (ClinicalTrials. gov 
NCT01441076). Canakinumab 
has also shown positive results [31]. Additional evidence for the 
role of IL-1β in BD derives from a trial with gevokizumab that has 
led to complete resolution of intraocular inflammation in both 
uveitis and retinal vasculitis [32].  
Sjogren’s syndrome (SS) is characterized by infiltration of 
mononuclear cells in the salivary and lacrimal glands, leading 
to dryness of both mouth and eyes. Although its pathogenesis 
remains unknown, several studies have hypothesized that sub-
verted cytokine pathways might contribute to the pathological 
setting of the syndrome. Highly increased concentrations of 
IL-1 have been found in the salivary fluid and peripheral blood 
of patients with SS, suggesting this cytokine as the master regu-
lator in the development of SS local and systemic manifesta-
tions [33]. In addition, an imbalance between salivary IL-1 
and IL-1 receptor antagonist (IL-1Ra) most likely promotes 
the typical inflammatory lesions in the mouth. Some authors 
have also hypothesized that IL-1β might display a proteolytic 
activity, disrupting acinar and ductal gland structure [34]. 
Anti-IL-1 agents are now regarded as potential treatment tools, 
and a randomized double-blind placebo-controlled trial has 
revealed that IL-1 inhibition with anakinra is able to reduce 
fatigue in patients with SS [35]. Recent data from a prospective 
double-blind randomized trial also demonstrate that targeting 
IL-1 by topical application of anakinra reduces dry eye disease-
related symptoms [36].
and pseudogout derives from the favorable results obtained 
with anakinra in an open-label study [15]. In line with these 
findings, Vitale et al. [16] recently reported three patients with 
chronic tophaceous gout unresponsive to standard therapy, 
in whom anakinra led to remarkable amelioration of joint 
symptoms within 24 hours. Interestingly, the patients were also 
affected by T2DM and, along with reduced joint symptoms, 
also achieved a marked improvement in glycemic control [16]. 
Moreover, a large study on crystal-induced arthritis demon-
strated the superior therapeutic effect of canakinumab and 
rilonacept as compared to corticosteroids [17,18]. A phase III 
study testing canakinumab efficacy in the prevention of gout 
attack recurrence is now ongoing for patients intolerant or 
unresponsive to colchicine (ClinicalTrials.gov NCT01362608). 
Adult-onset Still’s disease (AoSD) is a rare inflammatory 
disorder of undisclosed etiology, characterized by increased 
pro-inflammatory cytokines in the serum [19] and substantial 
risk of macrophage activation syndrome which occurs as a severe 
complication with a higher mortality rate than in children with 
systemic onset juvenile idiopathic arthritis, the pediatric counter-
part of AoSD. Robust evidence 
on IL-1 involvement in the 
pathogenesis of AoSD derives 
from the beneficial effects 
observed when treating these 
patients with IL-1 antagonists. 
Notably, in an open randomized 
multicenter study in 22 patients with AoSD, monotherapy with 
anakinra has been effective in those refractory to conventional 
treatments such as corticosteroids and methotrexate [20]. Also, 
canakinumab and rilonacept have proven effective in inhibiting 
IL-1 in AoSD [21,22].
tHe melting Pot of autoimmune disorders
The pathogenesis of rheumatoid arthritis (RA) has actually 
been related to multiple pro-inflammatory cytokines, such 
as TNFα and IL-1β [23], and understanding RA pathophysi-
ological mechanisms has clarified the role of cytokines as new 
potential targets for biological therapy. In this regard anakinra, 
alone or in combination with methotrexate, has been evaluated 
in several controlled studies of patients with RA, improving the 
disease course and preventing radiological progression of joint 
damage [24]. A phase II dose-finding study also evaluated the 
favorable response of canakinumab in patients with active RA 
despite ongoing methotrexate therapy [25]. 
The etiology of chronic uveitis remains uncertain, though 
this condition is the most frequent extra-articular sign of dif-
ferent systemic autoimmune rheumatologic disorders, such 
as the oligoarticular variant of juvenile idiopathic arthritis, 
seronegative spondyloarthritis, and Behçet’s disease (BD). 
The inflammatory process leading to uveitis is mainly driven 
anti-interleukin-1 agents may represent new 
weapons for treating autoimmune disorders, 
displaying, like autoinflammatory conditions, 
self-directed systemic inflammation in 
genetically predisposed individuals
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Chronic diffuse interstitial wall inflammation in the lung 
is the precondition for progressive pulmonary fibrosis, which 
characterizes all interstitial lung diseases. Alveolar macro-
phages are involved in different pulmonary inflammatory pro-
cesses through IL-1 hypersecretion after a host of exogenous 
and endogenous stimuli [37]. Several studies have revealed the 
presence of IL-1β in the pulmonary fibrous tissue, suggesting a 
causative link between IL-1 and fibrosis [38]. A genetic variabil-
ity in the IL1RN gene, encoding the physiological IL-1Ra, may 
also contribute to the pathogenesis of idiopathic pulmonary 
fibrosis [39]. NLRP3 inflammasome is probably involved in 
pneumoconiosis [40], and a phase I/II study is underway to test 
skin gene expression after administration of the IL-1 inhibitor 
rilonacept in patients with systemic sclerosis (ClinicalTrials.gov 
NCT01538719), though further studies are required to explore 
the exact role of IL-1 in the pathogenesis of pulmonary inflam-
matory processes in their entirety.
conclusive remarKs
This review has shown how the inflammasome works as an 
activating platform for the release of bioactive pro-inflam-
matory IL-1β. Dysegulation in this cascade may be caused by 
mutations in the genes coding for inflammasomal components 
and/or their interaction partners, leading to autoinflammatory 
scenarios. However, the contribution of deregulated inflamma-
somes to the field of autoimmune disorders, such as RA and SS, 
was recently suggested and corroborated by the efficacy of IL-1 
blockade in these conditions. New avenues for the therapy of 
such diseases will be paved in the near future and our way of 
managing these patients will likely be revolutionized. 
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Poelman et al. sought to retrospectively review a single-center 
experience using intravenous immunoglobulin (IVIG) for the 
treatment of refractory, active diffuse cutaneous systemic 
sclerosis (dcSSc). The mean modified Rodnan Skin score 
(mRSS) at baseline was compared to the mRSS at 6, 12, 18, 
and 24 months post-IVIG initiation by the paired Student t-test. 
Changes in mRSS at 6 and 12 months were also compared 
to data from historical controls of three large, negative, 
multicenter, randomized clinical trials of other medications 
[D-penicillamine (D-pen), recombinant human relaxin (relaxin), 
and oral bovine type I collagen (collagen)], and to patients 
treated with mycophenolate mofetil (MMF) alone using the 
Student t-test. Thirty patients were treated with adjunctive IVIG 
(2 g/kg/month) for refractory active dcSSc. The mean baseline 
mRSS of our cohort was 29.6 ± 7.2, and this significantly 
decreased to 24.1 ± 9.6 (n = 29, P = 0.0011) at 6 months, 22.5 
± 10.0 (n = 25, P = 0.0001) at 12 months, 20.6 ± 11.8 (n = 23, P 
= 0.0001) at 18 months, and 15.3 ± 6.4 (n = 15, P < 0.0001) at 
24 months. The mean change in mRSS at 6 months was not 
significantly different in the IVIG group (-5.3 ± 7.9) compared 
to the relaxin trial (-4.8 ± 6.99, P = 0.74) or MMF group (-3.4 
± 7.4, P = 0.26); however, at 12 months, the mean change in 
mRSS was significantly better in the IVIG group (-8 ± 8.3) than 
in the D-pen (-2.47 ± 8.6, P = 0.005) and collagen (-3.4 ± 7.12, P 
= 0.005) groups, and was comparable to the group of primary 
MMF responders (-7.1 ± 9, P = 0.67). The authors suggest that 
IVIG may be an effective adjunctive therapy for active dcSSc in 
patients in whom other therapies failed. 
J Rheumatol 2014;doi:10.3899/jrheum.140833
Eitan Israeli
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intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous 
systemic sclerosis
Adjuvants increase vaccine potency largely by activating innate 
immunity and promoting inflammation. Limiting the side effects 
of this inflammation is a major hurdle for adjuvant use in 
vaccines for humans. It has been difficult to improve on adjuvant 
safety because of a poor understanding of adjuvant mechanism 
and the empirical nature of adjuvant discovery and development 
historically. Wu et al. describe new principles for the rational 
optimization of small-molecule immune potentiators (SMIPs) 
targeting Toll-like receptor 7 as adjuvants with a predicted in- 
crease in their therapeutic indices. unlike traditional drugs, 
SMIP-based adjuvants need to have limited bioavailability and 
remain localized for optimal efficacy. These features also lead 
to temporally and spatially restricted inflammation that should 
decrease side effects. Through medicinal and formulation 
chemistry and extensive immunopharmacology, the authors 
show that in vivo potency can be increased with little to no 
systemic exposure, localized innate immune activation, and 
short in vivo residence times of SMIP-based adjuvants. This work 
provides a systematic and generalizable approach to engi- 
neering small molecules for use as vaccine adjuvants. 
Sci Transl Med 2014; 6: 263ra160
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rational design of small molecules as vaccine adjuvants
